Deploying a fully integrated biologics database at ADC Therapeutics
Antibody drug conjugates (ADCs) provide personalized therapeutic options in oncology via the innovative integration of monoclonal antibodies and a desired drug. However, the discovery and development of ADCs is complex and involves optimal conjugation strategies, linkers, and small molecule payloads.
Join Dr. Christopher Gallagher, Associate Director at ADC Therapeutics (ADCT), as he uncovers why ADCT deployed the Genedata Biologics® platform to streamline the entire ADC R&D process from development to delivery.
Genedata Biologics enables the registration and tracking of both complex biologics and small molecules, combining analytics and functional assay results into a ‘single source of truth’ across R&D. This significantly improves the throughput and efficiency of ADC discovery and accelerates research to identify solutions for patients faster.
Key learning objectives:
- Gain insights into the complex process of ADC development, including antibody engineering, expression, purification, bioconjugation, and characterization
- Enhance ADC discovery by implementing comprehensive registration and tracking for all ADCs and their unique components, including antibodies, linkers, payloads, DAR, and conjugation sites
- Learn about efficient capture, analysis, and visualization of in vitro and in vivo characterization data, including toxicology and PK studies, to evaluate ADC batches
- Streamline the ADC discovery process end-to-end by integrating ADC registration, analytics, functional assay results, and visualization into one system
Who should attend?
- Pharma/Biopharma/Biotech scientists working on ADCs, biologics, drug discovery, and preclinical testing
- Immuno-oncology experts focused on combination therapies, particularly integrating ADCs with immunotherapies
- Bioinformaticians who analyze and integrate complex biological data to support ADC development
- Conjugation chemists specializing in the chemical processes of linking drugs to antibodies
- CMC management & operations directors overseeing the chemistry, manufacturing, and controls (CMC) aspects of ADC production
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
Speakers
Dr. Christopher Gallagher obtained his PhD in Structural and Molecule Biology from the Francis Crick Institute & University College London. Dr. Gallagher then joined Union Chimique Belge (UCB) where he was involved in bispecific antibody screening and protein reagent generation and characterization. In 2021, he joined ADC Therapeutics (ADCT), where he established its in-house protein expression platform. As part of this work, he introduced Genedata Biologics® to ADCT and oversaw its deployment. He is now an Associate Director and heads up the protein expression and purification groups, as well as supervising the organization’s antibody engineering efforts.
Moderator
